使用SMS 201-995治疗促甲状腺激素分泌型垂体腺瘤患者后的视力改善情况。 - Suppr

Suppr

超能文献

Visual improvement with SMS 201-995 in a patient with a thyrotropin-secreting pituitary adenoma.

作者信息

Guillausseau P J, Chanson P, Timsit J, Warnet A, Lajeunie E, Duet M, Lubetski J

出版信息

N Engl J Med. 1987 Jul 2;317(1):53-4. doi: 10.1056/NEJM198707023170113.

DOI:10.1056/NEJM198707023170113

PMID:2884566

Abstract

摘要

相似文献

Visual improvement with SMS 201-995 in a patient with a thyrotropin-secreting pituitary adenoma.使用SMS 201-995治疗促甲状腺激素分泌型垂体腺瘤患者后的视力改善情况。

N Engl J Med. 1987 Jul 2;317(1):53-4. doi: 10.1056/NEJM198707023170113.

Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.用生长抑素类似物SMS 201-995对一名分泌促甲状腺激素和生长激素的垂体腺瘤患者进行长期治疗。

J Clin Endocrinol Metab. 1988 Mar;66(3):636-9. doi: 10.1210/jcem-66-3-636.

Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue.促甲状腺素分泌型垂体腺瘤对长效生长抑素类似物的反应

N Engl J Med. 1987 Jul 2;317(1):12-7. doi: 10.1056/NEJM198707023170103.

[TSH-secreting pituitary adenomas].[促甲状腺激素分泌型垂体腺瘤]

Rev Med Liege. 1988 May 15;43(10):396-402.

Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995).长效生长抑素类似物奥曲肽（SMS 201-995）治疗原发性促甲状腺素分泌型垂体腺瘤的缩小情况

Acta Endocrinol (Copenh). 1991 Apr;124(4):487-91. doi: 10.1530/acta.0.1240487.

Lanreotide autogel-induced tumour shrinkage in thyrotropin-secreting pituitary macroadenomas.兰瑞肽缓释凝胶诱导促甲状腺素分泌型垂体大腺瘤肿瘤缩小。

Clin Endocrinol (Oxf). 2011 Mar;74(3):406-8. doi: 10.1111/j.1365-2265.2010.03929.x.

[Hypophyseal thyrotropin adenomas at Yaounde (Cameroon). Analysis of two case reports: improvement with somatostatin analogue (SMS 201-995)].[喀麦隆雅温得的垂体促甲状腺素腺瘤。两例病例报告分析：生长抑素类似物（SMS 201-995）治疗有效]

Tunis Med. 1999 Mar;77(3):154-8.

Somatostatin analogs in the treatment of acromegaly.生长抑素类似物在肢端肥大症治疗中的应用

Endocrinol Metab Clin North Am. 1992 Sep;21(3):737-52.

[Response of thyrotropinoma to somatostatin analogues: report of a case].[促甲状腺素瘤对生长抑素类似物的反应：一例报告]

An Med Interna. 2001 Dec;18(12):663.

Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).用醋酸奥曲肽（生长抑素类似物）治疗促甲状腺素分泌型垂体腺瘤后肿瘤体积缩小

Eur J Endocrinol. 1994 Jul;131(1):109-12. doi: 10.1530/eje.0.1310109.

引用本文的文献

TSH-Secreting Pituitary Adenoma: Current Management and Review.促甲状腺激素分泌型垂体腺瘤：当前的管理与综述

Skull Base Surg. 1997;7(2):89-93. doi: 10.1055/s-2008-1058614.

Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.奥曲肽用于促甲状腺素分泌型垂体腺瘤的长期术前管理。

J Endocrinol Invest. 1998 Dec;21(11):775-8. doi: 10.1007/BF03348045.

Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.使用单光子发射断层扫描对一名分泌促甲状腺激素/催乳素的垂体大腺瘤患者进行体内多巴胺D2和生长抑素受体成像。

Eur J Nucl Med. 1993 Jun;20(6):555-61. doi: 10.1007/BF00175168.

Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.奥曲肽的临床药代动力学。在垂体肿瘤患者中的治疗应用。

Clin Pharmacokinet. 1993 Nov;25(5):375-91. doi: 10.2165/00003088-199325050-00004.

Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.奥曲肽。对其药效学和药代动力学特性以及在与肽分泌过多相关病症中的治疗潜力的综述。

Drugs. 1989 Nov;38(5):658-702. doi: 10.2165/00003495-198938050-00002.

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide.用奥曲肽治疗促甲状腺素分泌型垂体腺瘤的缩小情况。

Postgrad Med J. 1991 May;67(787):466-8. doi: 10.1136/pgmj.67.787.466.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验